BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 30743998)

  • 1. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
    Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging pathways for precision medicine in management of cholangiocarcinoma.
    Rahnemai-Azar AA; Abbasi A; Acher AW; Weber SM; Pawlik TM
    Surg Oncol; 2020 Dec; 35():47-55. PubMed ID: 32827952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies.
    Brandi G; Farioli A; Astolfi A; Biasco G; Tavolari S
    Oncotarget; 2015 Jun; 6(17):14744-53. PubMed ID: 26142706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
    Marks EI; Yee NS
    World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
    Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
    Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholangiocarcinoma: novel therapeutic targets.
    Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
    Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Treatment for Cholangiocarcinoma.
    Sookprasert A; Wirasorn K; Chindaprasirt J; Watcharenwong P; Sanlung T; Putraveephong S
    Recent Results Cancer Res; 2023; 219():223-244. PubMed ID: 37660335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical management of cholangiocarcinomas in 2015].
    Marret G; Neuzillet C; Rousseau B; Tournigand C
    Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
    Rahnemai-Azar AA; Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
    [No Abstract]   [Full Text] [Related]  

  • 20. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
    Lodl E; Ramnaraign B; Sahin I; Wheeler S
    J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.